未知生产厂商
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.
BZL101 works by eliciting a cancer cell’s innate mechanism of self-suicide or apoptosis. The drug selectively releases Apoptosis Inducing Factor-1 (AIF1) from a cancer cell’s mitochondrial membrane. AIF then moves to the cell’s nucleus, disintegrating the DNA structure, and fragmenting and killing the cancer cell.
Investigated for use/treatment in breast cancer.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
